Researchers at Florida State University are now reporting in the latest issue of PLOS One, that by looking at altered signal genetic pathways, it may be possible to come up with new, more targeted prostate cancer treatments.
BRCA mutations and co-occurring gene alterations in prostate cancer suggest that some patients might benefit from oral poly (ADP-ribose) polymerase (PARP) inhibitors.
Investigators at the University of Virginia (UVA) Health System are now reporting that there is a common connection between the use radiation and androgen deprivation therapy.
The study demonstrated that treatment of abiraterone acetate was associated with longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer.
Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.
A third of men with treatment-resistant advanced prostate cancer show promising clinical responses to olaparib, according to findings from the phase II TOPARP-A trial, the first published clinical study of a gene-targeted treatment for prostate cancer.
Germline BRCA2 mutations are associated with poorer outcome in prostate cancer and now researchers think they know why.
Clinicians may now have a better tool for guiding therapy in men with prostate cancer who have had a prostatectomy and salvage radiation therapy (SRT).
More aggressive prostate tumor phenotypes exhibit stem cell-like gene expression patterns, report researchers at the University of California, Los Angeles (UCLA).
In this interview, Dr. Mario Eisenberger talks about potential new combination therapies for advanced prostate cancer that are currently being tested in clinical trials.